Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces B cell
responses that continue to evolve for at least a year. During that time, memory B cells …

Here we report on the antibody and memory B cell responses of a cohort of 20 volunteers
who received the Moderna (mRNA-1273) or Pfizer–BioNTech (BNT162b2) vaccine against …

The Omicron variant of SARS-CoV-2 infected many vaccinated and convalescent
individuals,–. Despite the reduced protection from infection, individuals who received three …

The primary two-dose SARS-CoV-2 mRNA vaccine series are strongly immunogenic in
humans, but the emergence of highly infectious variants necessitated additional doses and …

Multiple SARS-CoV-2 variants have mutations in the spike receptor binding domain (RBD)
with potential to evade neutralizing antibody. In particular, the Beta and Omicron variants …

The emergence of SARS-CoV-2 variants is jeopardizing the effectiveness of current
vaccines and limiting the application of monoclonal antibody-based therapy for COVID-19 …

The emergence of SARS-CoV-2 variants with mutations in major neutralizing antibody-
binding sites can affect humoral immunity induced by infection or vaccination,,,,–. Here we …

More than one year after its inception, the coronavirus disease 2019 (COVID-19) pandemic
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains difficult …

Feedback inhibition of humoral immunity by antibodies was first documented in 1909.
Subsequent studies showed that, depending on the context, antibodies can enhance or …

Understanding the longitudinal dynamics of antibody immunity following heterologous SAR-
CoV-2 breakthrough infection will inform the development of next-generation vaccines …